Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections
Completed · Phase 1 · NCT02134301
Conditions: Gram-positive Bacterial Infections
At a glance
- Research payments reported, 2025
- $21,670
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 41
About the trial
- Sponsor
- Melinta Therapeutics, LLC
- Tested
- Oritavancin (drug)
- Dates
- Started 2014-05; completion 2025-11-04
- Results posted
- Not yet
The purpose of this Phase 1 trial is to evaluate the pharmacokinetics (PK), safety and tolerability of oritavancin in participants \<18 years old with a confirmed or suspected bacterial infection.
From ClinicalTrials.gov, last updated 2025-12-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Melinta Therapeutics, LLC reported $21,670 in research payments for this study in 2025 (6 payments).
Products named: Orbactiv
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- John S. Bradley, M.D. Pediatric Infectious Disease · San Diego, CA
- Janice E. Sullivan, MD Pediatric Critical Care · Louisville, KY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of California, San Diego $16,350
- University of Louisville Research Foundation $5,320
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.